SLNO

Soleno Therapeutics Inc

SLNO.US soleno.life + Research + Basket
CIK 0001484565
Employees 182
Phone 650 213 8444
Fiscal year end December
IPO Nov 13, 2014
Address 100 Marine Parkway, Redwood City, CA, United States, 94065
Price N/A
USD · NASDAQ
52-week range
29.43
69.99
Market Cap
2.76B
P/E Ratio
27.47
Forward P/E
13.12
Book Value
8.61
Div. Yield
N/A
% Institutions
111.53%
% Insiders
1.31%

1 Year

-29.9%

3 Year

+995.2%

10 Year

-44.8%
Description

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.

Actions

Add an action for SLNO.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Anish Bhatnagar M.D. Chairman, President & CEO 1970
Mr. James H. MacKaness Executive Officer 1964
Ms. Meredith Manning M.B.A. Chief Commercial Officer 1972
Mr. Kevin Norrett M.B.A., M.S. Chief Business Officer 1973
Dr. Manher A. Joshi M.D. Chief Development Officer 1968
Ms. Jennifer Fulk Chief Financial Officer 1977
Mr. Jesse Schumaker General Counsel NA
Ms. Lauren Budesheim Senior Vice President of People NA
Ms. Kristen Yen M.S. Senior Vice President of Global Clinical Operations and Patient Advocacy 1969
Dr. Neil M. Cowen M.B.A., Ph.D. Senior Vice President of New Product Planning NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Jul 01, 2025 Patricia C Hirano N/A Sale 3.83K $82.76 $316.97K SEC
Jun 24, 2025 Patricia C Hirano N/A Sale 266.00 $84.25 $22.41K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HHG PLC 7.10M Mar 31, 2026 13.62% $0.11 -1.10%
FMR Inc 5.79M Mar 31, 2026 11.11% $0.01 -28.36%
Wellington Management Company LLP 4.43M Mar 31, 2026 8.49% $0.03 33.22%
BlackRock Inc 3.74M Mar 31, 2026 7.18% $0.00 -3.33%
Vanguard Group Inc 3.06M Dec 31, 2025 5.87% $0.00 9.02%
State Street Corp 2.68M Mar 31, 2026 5.14% $0.00 1.18%
venBio Select Advisor LLC 2.30M Mar 31, 2026 4.41% $0.76 -20.69%
Vanguard Capital Management, LLC 2.15M Mar 31, 2026 4.13% $0.00 0.00%
Nantahala Capital Management, LLC 1.74M Mar 31, 2026 3.35% $2.15 32.73%
Polar Capital Holdings PLC 1.70M Mar 31, 2026 3.26% $0.20 49.42%
Khrom Capital Management, LLC 1.51M Mar 31, 2026 2.90% $4.63 0.00%
Geode Capital Management, LLC 1.24M Mar 31, 2026 2.37% $0.00 6.38%
Woodline Partners LP 1.11M Mar 31, 2026 2.13% $0.14 0.03%
Deep Track Capital, LP 1.08M Mar 31, 2026 2.07% $0.59 7.87%
T. Rowe Price Associates, Inc. 1.03M Mar 31, 2026 1.97% $0.00 -69.09%
BRAIDWELL LP 959.26K Mar 31, 2026 1.84% $1.07 -19.24%
Readystate Asset Management LP 874.45K Dec 31, 2025 1.68% $1.64 324.89%
Franklin Resources Inc 835.18K Mar 31, 2026 1.60% $0.01 1.36%
Vestal Point Capital LP 730.00K Mar 31, 2026 1.40% $0.68 0.00%
COMMODORE CAPITAL LP 652.43K Mar 31, 2026 1.25% $1.26 -45.63%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Health Care Inv 3.01M 5.78% ▲ 52.26% Mar 31, 2026
2 Vanguard Total Stock Mkt Idx Inv 1.56M 3.00% ▲ 0.29% Apr 30, 2026
3 Janus Henderson Global Life Sciences 987.38K 1.89% ▼ 1.46% Mar 31, 2026
4 Janus Henderson Global Life Sciences D 987.38K 1.89% ▼ 0.24% Mar 31, 2026
5 Janus Global Life Science AUSD 910.95K 1.75% ▲ 4.46% Mar 31, 2026
6 International Biotechnology Ord 648.53K 1.24% ▲ 0.00% Apr 30, 2026
7 Janus Henderson Triton D 614.56K 1.18% ▲ 0.00% Mar 31, 2026
8 Janus Henderson US SMID Cap Growth 614.56K 1.18% ▼ 2.40% Mar 31, 2026
9 Janus Henderson Hrzn Biotec E2 USD 614.07K 1.18% ▲ 0.00% Mar 31, 2026
10 Vanguard Institutional Extnd Mkt Idx Tr 551.75K 1.06% ▲ 1.18% Apr 30, 2026

Financial Highlights

▼
Market Cap: $2.76B
EBITDA: $91.52M
P/E Ratio: $27.47
PEG Ratio: $0.00
Book Value: $8.61
Earnings/Share: $1.93
Profit Margin: 33.70%
Operating Margin: 33.57%
ROA (TTM): 12.07%
ROE (TTM): 26.38%
Revenue (TTM): $285.01M
Revenue/Share (TTM): $5.45
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $2.56B
Trailing P/E: 27.47
Forward P/E: 13.12

Shares Statistics

Shares Outstanding: 52.12M
Shares Float: 51.46M
% Insiders: 1.31%
% Institutions: 111.53%
Shares Short: 6.53M
Shares Short (Prior Month): 5.80M
Short Ratio: 1.01
Short % Float: 17.89%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$190.41M
Cost of Goods Sold
adjust
$-2.70M
Gross Profit
subtotal
$187.71M
SG&A
adjust
$-29.26M
R&D
adjust
$-40.63M
Other Operating Expense
adjust
$-102.87M
Operating Income
subtotal
$14.95M
Other / Non-Operating Items
adjust
$5.94M
Net Income
subtotal
$20.89M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SLNO.US!